The clinical success of re-challenging patients with a different TKI after progression is not just about hitting VEGF harder. TKIs are 'dirty' drugs that also target other kinases like MET and AXL, which are present on immune cells like tumor-associated macrophages (TAMs), providing a distinct immunomodulatory effect.

Contrary to the long-held theory of vessel normalization, TKIs in Renal Cell Carcinoma (RCC) work by ablating blood vessels. This induces massive hypoxia, which surprisingly correlates with a better initial therapeutic response, mirroring clinical observations of necrosis in responding tumors.

A specific macrophage population expressing SPP1 serves as a novel biomarker for true, tissue-level hypoxia. This allows researchers to distinguish drug-induced hypoxia from the 'pseudo-hypoxic' state caused by VHL deficiency, which has been a major challenge in studying RCC biology and treatment response.

An FDA analysis showed the survival curve for kidney cancer patients on IO-IO therapy (ipinevo) is much flatter for those with early tumor growth compared to IO-TKI regimens. This suggests early progression on a dual-mechanism IO-TKI therapy indicates true resistance, while on IO-IO it could be delayed response.

The NEOADORA trial showed lower-than-expected pathologic complete response (pathCR) rates for neoadjuvant osimertinib (<10%), even with chemotherapy. This suggests EGFR TKIs primarily halt tumor growth (cytostatic) rather than eradicate tumor cells (cytotoxic), contrasting with the higher pathCR rates seen with chemo-immunotherapy.

Aggressive treatments like radiation and chemotherapy induce immense metabolic stress, causing blood sugar to spike. This pushes the patient's body into a metabolic "red zone," which can create an environment that strengthens and feeds any remaining resistant tumor cells.

There is an inherent selection bias in RCC preclinical models. The tumors that successfully grow in mice, whether genetically engineered or patient-derived, tend to be the more aggressive, de-differentiated phenotypes. It is very difficult to model the common, low-grade, indolent clear cell tumors often seen in the clinic.

The next major advance in adjuvant kidney cancer will be a biomarker to select who needs treatment. The key is developing a Minimal Residual Disease (MRD) test based on the epigenome (e.g., chromatin modifications) rather than just ctDNA mutations. This is because the critical biological signals in RCC are found in epigenetic regulation, not just the genome.

A sophisticated concern regarding the HIF-2 inhibitor belzutifan is its potential to diminish kidney cancer's antigenicity by reducing human endogenous retrovirus expression. While providing an early benefit, this could theoretically make tumors less responsive to subsequent immunotherapies, negatively impacting long-term outcomes—a critical consideration for sequencing.